Couverture de The East-West Bio Brief

The East-West Bio Brief

The East-West Bio Brief

De : Basil Lui
Écouter gratuitement

Offres de saison | 0,99 € par mois pendant les 3 premiers mois

5,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
À propos de ce contenu audio
Biotech and beyond, from China, Asia and the West. Over half of global biotech licensing value comes from China, and the first signal often shows up in Chinese. Basil Lui (X: @basillui) and Ning turn primary sources into what matters for deals: a daily brief Tuesday to Sunday and a weekly roundup on Mondays. Beyond Biotech: health tech, diagnostics, AI drug discovery, lab automation, pet care and wearables. For BD teams, VCs and family offices. https://eastwestbiobrief.com Both voices are AI-cloned. Basil Lui is the real person behind the show; Ning is an AI co-host. Not investment advice.Basil Lui Economie Finances privées
Épisodes
  • Daily, Fri 20 Nov: Good fences make good neighbours? Washington's warning on China drug deals
    Nov 20 2026

    A US congressional commission says licensing deals are sending money and know-how to Chinese biotechs. The same week, a Boston investor opened in Shanghai, and Novartis showcased a blood-pressure drug that started in Shanghai. The National Security Commission on Emerging Biotechnology analysed 57 deals between 15 of the biggest drugmakers in the US market and 42 Chinese biotechs from January 2023 to October 2026, and supports a proposed US Treasury outbound-investment rule under the COINS Act (comments close 7 December). Plus AbbVie's $40 million upfront for Cologne's DISCO Pharmaceuticals, set against the $650 million it paid in January for RemeGen's (荣昌生物) clinical-stage RC148 (not like-for-like); QCZ484 on Novartis's investor-day stage, which Argo Biopharma (舶望制药) says came from Argo in Shanghai under a licensing deal; Merck's research deal with Isomorphic Labs; a reported Sanofi look at Insmed; and a closed-loop brain stimulator for depression.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui (X: @basillui) is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil has no personal holding in any company mentioned.

    Weekly roundup: subscribe to The East-West Bio Brief newsletter on LinkedIn

    Chapters
    0:00 Intro and AI-voice disclosure
    1:06 The commission's warning: 57 deals, earlier and bigger
    3:58 The counterpoint: RA Capital's door in Shanghai
    4:30 The price of early science: AbbVie, RemeGen and Starna
    5:55 Quick hits: Novartis, Merck, Sanofi
    8:33 Beyond biotech: a closed-loop brain stimulator
    9:03 What to watch and sign-off

    Key sources: NSCEB: 'Innovated in China: The PRC's Progress Towards Capturing the U.S. Pharmaceutical Market' (18 Nov 2026) · NSCEB: 'China is Closing the Biopharma Innovation Gap' (19 Nov 2026) · South China Morning Post: RA Capital opens Shanghai office (19 Nov 2026)

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    10 min
  • Daily, Thu 19 Nov: If you can't beat them, license them? Pfizer's $330M CAR-T bet on China
    Nov 18 2026

    A day after Pfizer's CEO named Chinese biotechs as his main competition by 2030, Pfizer agreed to pay a Suzhou company $330 million upfront for CAR-T made inside the body. Starna Therapeutics (星锐医药) licensed Pfizer three early in vivo CAR-T programmes for autoimmune disease outside Greater China, with up to $2.3 billion more in milestones plus royalties. Plus the FDA's published letter on Akeso's (康方生物) ivonescimab, which says 93% of the progression-free survival events in its key trial came from patients in China; Insilico Medicine's four months from candidate to first human for a non-opioid pain drug; Merck stopping nemtabrutinib; and GSK's Nelkarmi approval in ALK-positive lung cancer.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui (X: @basillui) is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil has no personal holding in any company mentioned.

    Weekly roundup: subscribe to The East-West Bio Brief newsletter on LinkedIn

    Chapters
    0:00 Intro and AI-voice disclosure
    1:07 Pfizer and Starna: CAR-T made inside the body
    4:36 The ivonescimab letter: more than the survival miss
    6:23 Quick hits: Insilico, Merck, Nelkarmi
    8:57 What to watch and sign-off

    Key sources: Pfizer: exclusive licensing agreement with Starna Therapeutics (18 Nov 2026) · FDA: complete response letter database (BLA 761524, ivonescimab) · Insilico Medicine: ISM9528 first-in-human dosing (HKEX, 17 Nov 2026) · Merck: update on the BELLWAVE programme (17 Nov 2026)

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    10 min
  • Daily, Wed 18 Nov: Software eats the world, really? A $5B bet on AI-designed drugs
    Nov 17 2026

    Andreessen's 2011 line meets a $5 billion bet on AI-designed medicines, before a single human trial. Isomorphic Labs, the London-based AI drug-design company spun out of Google DeepMind, raised $5 billion, with Singapore's Temasek among its existing backers, while two of the five AI drug-discovery companies with drugs in Phase 3 are running those trials in China. Plus South Korea's AriBio and its once-daily Alzheimer's pill AR1001, with Fosun Pharma (复星医药) weighing its option; AstraZeneca's Klygefa for generalised myasthenia gravis, which Japan approved first; quick hits on Roche's Wilserdly, Takeda's Innovent-discovered (信达生物) stomach-cancer drug, Akeso's (康方生物) gumokimab and OBI Pharma's Novartis deal; and wearables that want to treat you, not just track you, from Oura to Huawei and Samsung.

    Full transcript and all sources for this episode

    Both voices are AI-cloned. Basil Lui (X: @basillui) is the real person behind the show; Ning is an AI co-host. Personal views, not investment or medical advice. Basil has no personal holding in any company mentioned.

    Weekly roundup: subscribe to The East-West Bio Brief newsletter on LinkedIn

    Chapters
    0:00 Intro and AI-voice disclosure
    0:50 Isomorphic: $5B, no patient yet
    2:37 A Korean Alzheimer's pill, a Chinese option
    4:43 Klygefa: Japan said yes first
    6:47 Quick hits: Wilserdly, Takeda, Akeso, OBI
    8:31 Wearables that want to treat you
    9:45 What to watch and sign-off

    Key sources: Isomorphic Labs: Series C investment round (17 Nov 2026) · AriBio: POLARIS-AD Phase 3 topline results (16 Nov 2026) · AstraZeneca: Klygefa (gefurulimab) approved in the US (16 Nov 2026) · Roche: FDA approves Wilserdly (giredestrant) (16 Nov 2026)

    Also listen on: Apple Podcasts · Amazon Music · YouTube

    Afficher plus Afficher moins
    11 min
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment